Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,659
archived clinical trials in
Metabolic

A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated:  7/6/2016
Clinical Research Facility
mi
from
Irvine, CA
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Status: Enrolling
Updated: 7/6/2016
Clinical Research Facility
mi
from
Irvine, CA
Click here to add this to my saved trials
Change of Fructose to Fat in South Asians
Fructose-induced Hepatic De Novo Lipogenesis in South Asians
Status: Enrolling
Updated:  7/20/2016
The Rogosin Institute
mi
from
New York, NY
Change of Fructose to Fat in South Asians
Fructose-induced Hepatic De Novo Lipogenesis in South Asians
Status: Enrolling
Updated: 7/20/2016
The Rogosin Institute
mi
from
New York, NY
Click here to add this to my saved trials
Change of Fructose to Fat in South Asians
Fructose-induced Hepatic De Novo Lipogenesis in South Asians
Status: Enrolling
Updated:  7/20/2016
Weill Cornell Medical College Clinical and Translational Science Center (CTSC)
mi
from
New York, NY
Change of Fructose to Fat in South Asians
Fructose-induced Hepatic De Novo Lipogenesis in South Asians
Status: Enrolling
Updated: 7/20/2016
Weill Cornell Medical College Clinical and Translational Science Center (CTSC)
mi
from
New York, NY
Click here to add this to my saved trials
Effects of Almond Intake on Atherogenic Dyslipidemia of the Metabolic Syndrome
Effects of Almond Intake on Atherogenic Dyslipidemia of the Metabolic Syndrome
Status: Enrolling
Updated:  8/1/2016
Cholesterol Research Center
mi
from
Berkeley, CA
Effects of Almond Intake on Atherogenic Dyslipidemia of the Metabolic Syndrome
Effects of Almond Intake on Atherogenic Dyslipidemia of the Metabolic Syndrome
Status: Enrolling
Updated: 8/1/2016
Cholesterol Research Center
mi
from
Berkeley, CA
Click here to add this to my saved trials
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
An Open-Label, 2-Cohort Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®), to Assess the Dose Proportionality of Epanova™, and to Compare the Systemic Exposure of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Following Multiple Doses of Epanova™ and Vascepa® in Healthy Normal Subjects
Status: Enrolling
Updated:  8/16/2016
Celerion
mi
from
Neptune, NJ
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
An Open-Label, 2-Cohort Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®), to Assess the Dose Proportionality of Epanova™, and to Compare the Systemic Exposure of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Following Multiple Doses of Epanova™ and Vascepa® in Healthy Normal Subjects
Status: Enrolling
Updated: 8/16/2016
Celerion
mi
from
Neptune, NJ
Click here to add this to my saved trials
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
Status: Enrolling
Updated:  12/14/2016
Tufts University School of Medicine
mi
from
Boston, MA
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
Status: Enrolling
Updated: 12/14/2016
Tufts University School of Medicine
mi
from
Boston, MA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Oakland, CA
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Oakland, CA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Orange, CA
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Wilmington, DE
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Wilmington, DE
Click here to add this to my saved trials
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Washington,
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Orlando, FL
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Honolulu, HI
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Chicago, IL
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
New York, NY
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Seattle, WA
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Research Site
mi
from
Cordoba,
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Research Site
mi
from
Cordoba,
Click here to add this to my saved trials
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Oakland, CA
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Oakland, CA
Click here to add this to my saved trials
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Manhasset, NY
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Manhasset, NY
Click here to add this to my saved trials
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated:  12/19/2016
mi
from
Monza,
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status: Enrolling
Updated: 12/19/2016
mi
from
Monza,
Click here to add this to my saved trials
Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
Status: Enrolling
Updated:  1/17/2017
Children's Hospital of Orange County
mi
from
Orange, CA
Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
Status: Enrolling
Updated: 1/17/2017
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
Status: Enrolling
Updated:  1/17/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
Status: Enrolling
Updated: 1/17/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status: Enrolling
Updated:  1/23/2017
Children's Hospital Oakland
mi
from
Oakland, CA
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status: Enrolling
Updated: 1/23/2017
Children's Hospital Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status: Enrolling
Updated:  1/23/2017
Children's Hospital of Orange County
mi
from
Orange, CA
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status: Enrolling
Updated: 1/23/2017
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status: Enrolling
Updated:  1/23/2017
Emory Healthcare
mi
from
Decatur, GA
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status: Enrolling
Updated: 1/23/2017
Emory Healthcare
mi
from
Decatur, GA
Click here to add this to my saved trials
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status: Enrolling
Updated:  1/23/2017
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status: Enrolling
Updated: 1/23/2017
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status: Enrolling
Updated:  1/23/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status: Enrolling
Updated: 1/23/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status: Enrolling
Updated:  1/23/2017
University Of Utah Hospital
mi
from
Salt Lake City, UT
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status: Enrolling
Updated: 1/23/2017
University Of Utah Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
Status: Enrolling
Updated:  2/2/2017
Clinical Research Facility
mi
from
Pittsburg, PA
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
Status: Enrolling
Updated: 2/2/2017
Clinical Research Facility
mi
from
Pittsburg, PA
Click here to add this to my saved trials
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
Status: Enrolling
Updated:  2/2/2017
mi
from
Porte Alegre,
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
Status: Enrolling
Updated: 2/2/2017
mi
from
Porte Alegre,
Click here to add this to my saved trials
A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
An Open-label Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function
Status: Enrolling
Updated:  2/9/2017
Clinical Research Facility
mi
from
Miami, FL
A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
An Open-label Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function
Status: Enrolling
Updated: 2/9/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
An Open-label Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function
Status: Enrolling
Updated:  2/9/2017
Clinical Research Facility
mi
from
Knoxville, TN
A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
An Open-label Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function
Status: Enrolling
Updated: 2/9/2017
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis
Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis
Status: Enrolling
Updated:  2/9/2017
Northwestern University preventive Cardiology Center
mi
from
Chicago, IL
Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis
Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis
Status: Enrolling
Updated: 2/9/2017
Northwestern University preventive Cardiology Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Randomized Controlled Trial Testing The Effect Of A Multi-Nutrient Fortified Juice
A Randomized Controlled Trial Testing the Effect of a Multi-nutrient Fortified Juice
Status: Enrolling
Updated:  2/27/2017
Boston Med Ctr
mi
from
Boston, MA
A Randomized Controlled Trial Testing The Effect Of A Multi-Nutrient Fortified Juice
A Randomized Controlled Trial Testing the Effect of a Multi-nutrient Fortified Juice
Status: Enrolling
Updated: 2/27/2017
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Supplementation With Omega-3: Mechanism of Action
Supplementation With Omega-3: Mechanism of Action
Status: Enrolling
Updated:  2/28/2017
Johns Hopkins University
mi
from
Baltimore, MD
Supplementation With Omega-3: Mechanism of Action
Supplementation With Omega-3: Mechanism of Action
Status: Enrolling
Updated: 2/28/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
An Open-label Two-stage Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated:  3/7/2017
Clinical Research Facility
mi
from
Miami, FL
A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
An Open-label Two-stage Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated: 3/7/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
An Open-label Two-stage Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated:  3/7/2017
Clinical Research Facility
mi
from
St. Paul, MN
A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
An Open-label Two-stage Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated: 3/7/2017
Clinical Research Facility
mi
from
St. Paul, MN
Click here to add this to my saved trials
A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
An Open-label Two-stage Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated:  3/7/2017
Clinical Research Facility
mi
from
Knoxville, TN
A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
An Open-label Two-stage Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Enrolling
Updated: 3/7/2017
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic
Prospective, Randomized Study of Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic Containers.
Status: Enrolling
Updated:  3/13/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic
Prospective, Randomized Study of Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic Containers.
Status: Enrolling
Updated: 3/13/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Exploration of Immunity in Gaucher Disease
Prospective Study of Macrophage Activation and Cross Talk Between Immune System Elements in Subjects With Gaucher Disease
Status: Enrolling
Updated:  4/3/2017
Lysosomal Diseases Research and Treatment Center, CFCT
mi
from
Fairfax, VA
Exploration of Immunity in Gaucher Disease
Prospective Study of Macrophage Activation and Cross Talk Between Immune System Elements in Subjects With Gaucher Disease
Status: Enrolling
Updated: 4/3/2017
Lysosomal Diseases Research and Treatment Center, CFCT
mi
from
Fairfax, VA
Click here to add this to my saved trials
Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta
Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta
Status: Enrolling
Updated:  4/3/2017
O&O Alpan
mi
from
Fairfax, VA
Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta
Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta
Status: Enrolling
Updated: 4/3/2017
O&O Alpan
mi
from
Fairfax, VA
Click here to add this to my saved trials
Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)
Open-label Dose-titration Study of the Tolerability and Efficacy of Cinacalcet to Treat Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia
Status: Enrolling
Updated:  5/31/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)
Open-label Dose-titration Study of the Tolerability and Efficacy of Cinacalcet to Treat Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia
Status: Enrolling
Updated: 5/31/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Effects of Omega-3 Fatty Acids on Markers of Inflammation
Effects of Plant and Marine Omega-3 (w-3) Fatty Acids on Inflammatory Markers In Insulin Resistant Adults
Status: Enrolling
Updated:  5/31/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Effects of Omega-3 Fatty Acids on Markers of Inflammation
Effects of Plant and Marine Omega-3 (w-3) Fatty Acids on Inflammatory Markers In Insulin Resistant Adults
Status: Enrolling
Updated: 5/31/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Costa Mesa, CA
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Miami, FL
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Orlando, FL
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects
OM6X: An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza (Previously Omacor®) and Simvastatin Therapy in Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Mobile, AL
Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects
OM6X: An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza (Previously Omacor®) and Simvastatin Therapy in Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects
OM6X: An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza (Previously Omacor®) and Simvastatin Therapy in Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Encinitas, CA
Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects
OM6X: An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza (Previously Omacor®) and Simvastatin Therapy in Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Encinitas, CA
Click here to add this to my saved trials
Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects
OM6X: An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza (Previously Omacor®) and Simvastatin Therapy in Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Fresno, CA
Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects
OM6X: An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza (Previously Omacor®) and Simvastatin Therapy in Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Fresno, CA
Click here to add this to my saved trials
Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects
OM6X: An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza (Previously Omacor®) and Simvastatin Therapy in Hypertriglyceridemic Subjects
Status: Enrolling
Updated:  9/8/2017
GSK Investigational Site
mi
from
Greenbrae, CA
Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects
OM6X: An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza (Previously Omacor®) and Simvastatin Therapy in Hypertriglyceridemic Subjects
Status: Enrolling
Updated: 9/8/2017
GSK Investigational Site
mi
from
Greenbrae, CA
Click here to add this to my saved trials